1. Switzerland Stocks

  2. •

    Consumer non-durables

  3. •

    Household/Personal care
DSM-Firmenich AG

DSM-Firmenich AG

107.80
EUR
-0.05
(-0.05%)
20.52BMarket Cap
Feb 18Next Earn
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
75.92
55.66
45.57
34.22
34.84
- -
Basic EPS, GAAP
5.78
11.24
9.14
0.94
-4.17
- -
Free Cash Flow per Basic Share
- -
6.14
2.39
3.8
2.51
- -
Dividend per Share
- -
2.29
2.5
2.52
2.77
- -
Book Value per Share
- -
71.27
86.35
84.86
72.53
72.12
Tangible Book Value per Share
- -
37.12
15.72
16.71
11.37
10.48
Basic Weighted Avg Shares
151
151
233
265
259
249
Sales/Revenue/Turnover
11,444
8,390
10,627
9,054
9,034
- -
Operating Margin (%)
7.13
7.83
-4.77
6.09
7
- -
Depreciation Expense
- -
652
980
1,186
3,122
- -
Net Income, GAAP
872
1,700
2,137
250
-1,081
- -
Effective Tax Rate (%)
17.83
20.88
- -
15.13
20.77
- -
Profit Margin (%)
7.62
20.26
20.11
2.76
-11.97
- -
Working Capital
- -
5,570
4,325
4,439
3,300
4,264
LT Debt
- -
2,978
4,114
4,444
3,617
5,114
Total Equity
- -
10,845
23,070
22,697
18,423
17,974
Return on Invested Capital (%)
- -
- -
- -
1.65
2.15
- -
Return on Capital (%)
- -
- -
- -
1.29
-3.86
- -
Return on Common Equity (%)
- -
- -
12.67
1.1
-5.3
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,660
- -
1,651
LT Borrowings
3,231
- -
5,114
LT Finance Leases
386
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
252
250
247
Market Capitalization
17,220
15,648
20,519

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
8,893
- -
9,978
Cash, Cash Equivalents & STI
1,903
- -
2,308
Accounts Receivable, Net
1,841
- -
2,184
Inventories
2,121
- -
2,215
Total Current Liabilities
5,593
- -
5,714
Payables & Accruals
- -
- -
- -
ST Debt
1,660
- -
1,651
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-18.83%
Free Cash Flow
- -
- -
-35.29%
Net Income, GAAP
- -
- -
-532.4%
Sales/Revenue/Turnover
- -
- -
-0.22%
Total Cash Common Dividend
- -
- -
7.65%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
9,054
2025
- -
- -
- -
- -
9,034
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.94
2025
- -
- -
- -
- -
-4.17
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.52
2025
- -
- -
- -
- -
2.77
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Dimitri de Vreeze
Full Time Employees
28,550
Sector
Consumer non-durables
Industry
Household/Personal care
Address
Wurmisweg 576 Kaiseraugst AG Switzerland 4303
IPO Date
Feb 1, 2023
Website
dsm-firmenich.com
Similar Companies
Procter & Gamble Company (The) (NYSE:PG)
Cupid Limited (NSE:CUPID)
Hindustan Unilever Limited (NSE:HINDUNILVR)
Colgate-Palmolive (India) Limited (NSE:COLPAL)
Dabur India Limited (NSE:DABUR)
e.l.f. Beauty, Inc. (NYSE:ELF)
Business
DSM-Firmenich AG is a Swiss-domiciled company listed on Euronext Amsterdam that develops and produces science-based solutions in nutrition, health and beauty, encompassing vital nutrients, taste experiences, fragrances and ingredients for human and animal nutrition; perfumery and beauty products; taste, texture and health solutions for food and beverages; and health, nutrition and care offerings including early life nutrition, dietary supplements, medical nutrition and biomedical materials. The company operates through four primary segments: Perfumery & Beauty, providing raw materials for personal care; Health, Nutrition & Care, offering customized premixes, market-ready solutions and regulatory services including its direct-to-consumer I-Health business focused on gut and women's health; Taste, Texture & Health, delivering ingredients for food and beverage applications; and Animal Nutrition & Health, supplying vitamins from A to Z, enzymes, eubiotics, carotenoids, lipids, minerals and other specialties for sustainable animal farming. Founded through the 2023 merger of Royal DSM, established in 1902, and Firmenich, established in 1895, DSM-Firmenich AG maintains dual headquarters in Kaiseraugst, Switzerland, and Maastricht, Netherlands, with approximately 340 sites across nearly 60 countries and around 30,000 employees serving markets in North America, Europe, Asia, Latin America and other regions. Recent developments include the announcement in February 2024 to divest its Animal Nutrition & Health business unit; the sale of its stake in the Feed Enzymes Alliance to partner Novonesis; completion ahead of schedule of a €1.08 billion share buyback program initiated in February 2025; and in August 2024, conclusion of a new €1.8 billion revolving credit facility replacing prior arrangements.